Any feedback?
Literature summary for 3.4.24.29 extracted from
- The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin (2008), Biochem. J., 410, 157-165.
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| alpha2-Macroglobulin | a regulatory serpin, the initial N-terminal hydrolysis of alpha2-macroglobulin by aureolysin does not affect the serpin inhibitory activity, cleavage within its exposed reactive loop is associated with a decreased inhibitory activity, down to 23% of the control inhibitor | Staphylococcus aureus | |
| EDTA | - |
Staphylococcus aureus |  |
| plasminogen activator inhibitor-1 | PAI-1, a regulatory serpin, interaction analysis with aureolysin, overview, the proteolytic degradation of PAI-1 by aureolysin is associated with a drastic decrease in its capacity to inhibit uPA, down to 7% of the inhibitory activity of the control PAI-1 | Staphylococcus aureus | |
KM Value [mM]
| KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|
| additional information | - |
additional information | kinetics | Staphylococcus aureus |
Localization
| Localization | Comment | Organism | GeneOntology No. | Textmining |
|---|---|---|---|---|
| extracellular | aureolysin is secreted | Staphylococcus aureus | - |
- |
Metals/Ions
| Metals/Ions | Comment | Organism | Structure |
|---|---|---|---|
| Ca2+ | - |
Staphylococcus aureus | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Staphylococcus aureus | - |
wild-type strains 8325-4 and Newman, and clinical isolates | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| alpha2-macroglobulin + H2O | processing of the inhibitor, the initial N-terminal hydrolysis of alpha2-macroglobulin by aureolysin does not affect the serpin inhibitory activity, cleavage within its exposed reactive loop is associated with a decreased inhibitory activity, down to 23% of the control inhibitor | Staphylococcus aureus | ? | - |
? | |
| Gelatin + H2O | - |
Staphylococcus aureus | ? | - |
? | |
| plasminogen + H2O | - |
Staphylococcus aureus | angiostatin + mini-plasminogen | - |
? | |
| plasminogen activator inhibitor-1 + H2O | processing of the inhibitor, the proteolytic degradation of PAI-1 by aureolysin is associated with a drastic decrease in its capacity to inhibit uPA, down to 7% of the inhibitory activity of the control PAI-1 | Staphylococcus aureus | ? | - |
? | |
| pro-urokinase-type plasmin activator + H2O | human substrate, activation by cleavage into two enzyme chains, activity by wild-type strains 8325-4 and Newman, and clinical isolates, overview, no activity with N-terminal enzyme substrate mutants, overview | Staphylococcus aureus | 2 chains of urokinase-type plasmin activator | - |
? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| Aur | - |
Staphylococcus aureus |
Temperature Optimum [°C]
| Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|
| 37 | - |
assay at | Staphylococcus aureus |
pH Optimum
| pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|
| 7.4 | 7.8 | assay at | Staphylococcus aureus |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
